Stevanato Group S.p.A.

Overview

Stevanato Group S.p.A. is an Italy-based supplier to the pharmaceutical, biotechnology and life-sciences industries. Its business spans drug-containment and delivery solutions, diagnostic products, and engineering and equipment for pharmaceutical manufacturing, organized into Biopharmaceutical and Diagnostic Solutions and Engineering segments.[1] The company describes its purpose as “preserving the integrity of drugs” and its mission as working with partners worldwide to help make projects successful.[2]

Founded in 1949, Stevanato operates internationally: its 2025 company figures indicate a presence in 10 countries and products exported to 70 countries.[3][4] For 2025, it reported approximately 6,000 employees and consolidated revenue of €1,186.3 million.[4][5] [1]+4

Products & services

Stevanato Group’s drug-containment products include pharmaceutical glass pre-fillable syringes, cartridges, vials and ampoules. Its syringes are available in 0.5 ml to 5 ml sizes, in ready-to-fill EZ-fill® or bulk formats, with staked-needle, Luer-cone or Luer-lock configurations; the range also includes bypass syringes and double-chamber systems. Cartridges include bypass and multi-chamber designs for liquid or powder formulations, while vials are available in varied sizes and customized formats, including micro-vials.[6]+3 EZ-fill® containers are washed, depyrogenated and sterilized before delivery. The ready-to-fill system is designed to reduce customers’ need for washing and sterilization equipment, limit glass-to-glass contact and breakage, and work with existing filling lines.[10][11]

Higher-value glass offerings include NEXA®, associated with enhanced mechanical resistance and cosmetic quality, and ALBA®, designed to optimize drug–container interaction. The company also offers drug-delivery devices: Alina® variable-dose and Deora™ fixed-dose disposable pen injectors, both compatible with standard 3 ml glass cartridges, and the Vertiva™ wearable-injector brand. Its BDS portfolio also includes in-vitro diagnostic consumables and molecular diagnostic solutions. Analytical services at its Technology Excellence Centers include physical and chemical testing of packaging materials and components, functional characterization of drug-delivery devices, and analysis of drug–container interactions.[11]+3

Engineering products include automated, GMP-compliant equipment for assembling pen injectors, auto-injectors, nasal sprays, inhalers and on-body delivery systems, as well as secondary packaging, cartoning and palletizing equipment. Visual-inspection systems cover ampoules, vials, cartridges, syringes and bottles, with manual through high-speed automated options, including AI-enabled inspection. Glass-converting equipment includes automated forming lines for ampoules, vials, cartridges and syringes, plus tube loaders, after-forming lines and annealing ovens. Associated services include machine maintenance, line optimization and conversions, training, spare-parts support and AI-enabled digitization.[15]+4 In 2025, external-customer revenue was €1,038.174 million for BDS and €148.108 million for Engineering, approximately 87.5% and 12.5% of consolidated external revenue, respectively.[5] [6]+14

Geographic presence

In 2025, Stevanato Group generated revenue across four geographic markets: EMEA accounted for €690.3 million (58.2% of total revenue), North America €362.1 million (30.5%), APAC €101.5 million (8.6%), and South America €32.4 million (2.7%). The company sells in approximately 65 countries; principal markets include EMEA, Asia—particularly China—and the Americas, especially the United States, Mexico, and Brazil.[20]

The company’s 13 manufacturing plants are located in Italy, Germany, Slovakia, Brazil, Mexico, China, the United States, and Denmark. Its analytical-service sites are in Italy and the United States, while commercial offices are in Italy, China, Japan, and India. Headquarters and the registered office are in Piombino Dese, in Italy’s Padua area.[21]+2 At year-end 2025, Stevanato had 6,010 employees: 58% in Italy, 10% in Germany, 8% in the United States, 7% in Mexico, 5% in Brazil, 4% each in Slovakia and Denmark, and 3% in China; percentages may not total 100% because of rounding.[24] [20]+4

Business segments

Stevanato Group reports two business segments: **Biopharmaceutical and Diagnostic Solutions (BDS)**, focused on drug and reagent containment and delivery products and services, and diagnostic consumables; and **Engineering**, focused on equipment and technologies for pharmaceutical, biotechnology and life-sciences manufacturing, including inspection, assembly, packaging, serialization and glass converting.[25]

In FY2025, external-customer revenue was €1,038.2 million for BDS and €148.1 million for Engineering, out of €1,186.3 million in consolidated revenue. This equates to approximately **87.5% BDS** and **12.5% Engineering**.[5] The company’s total segment revenue figures also include inter-segment sales, so they are not directly comparable with consolidated revenue.[26] [25]+4

Company history

Giovanni Stevanato founded Soffieria Stella, a specialty glass manufacturer in Venice, in 1949; the business operated until 1959, when Stevanato Group was established in Piombino Dese. The Group’s pharmaceutical packaging and machinery capabilities developed through the establishment of Ompi in 1969 and Spami in 1971.[27][3]

The company expanded beyond Italy with the 2005 addition of Slovakian packaging producer Medical Glass. In 2007 it began production of EZ-fill® ready-to-use containers and acquired Optrel, a pharmaceutical inspection-equipment maker. Acquisitions in 2013 and 2016—including Innoscan, Balda, Medirio and SVM Automatik—broadened its inspection, medical-component, drug-delivery and automation capabilities.[28]

Stevanato Group listed on the New York Stock Exchange in July 2021. In 2022, Innoscan merged into SVM Automatik, later renamed Stevanato Group Denmark; the company also acquired Italian machinery specialist Perugini in 2023. In 2024, it unveiled a plant in Cisterna di Latina, its first site outside Piombino Dese producing high-value solutions, and appointed Franco Stevanato CEO.[29]+3 [27]+9

Sources

• Stevanato Group S.p.A. — Full financial report (2025 Y)
  25 citations

  [1][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28]
• www.stevanatogroup.com[2]
• www.stevanatogroup.com[3]
• www.stevanatogroup.com[4]
• ir.stevanatogroup.com[29]
• ir.stevanatogroup.com[30]
• ir.stevanatogroup.com[31]